Introduction
============

Exposure to chronic sustained hypoxia (CH) produces (1) an increase in ventilation that persists after normoxia is restored and (2) an increase in the acute hypoxic ventilatory response (HVR). This is called ventilatory acclimatization to hypoxia (VAH) and it depends on plasticity in both carotid body chemoreceptors and medullary respiratory control circuits ([@B32]). Plasticity in ventilatory control circuits can also be produced by other patterns of hypoxia with similar results. For example, acute intermittent hypoxia produces long term facilitation (LTF) with increases in ventilation and phrenic nerve activity that persist in normoxia after the hypoxia protocol, and increases in the HVR to successive bouts of intermittent hypoxia \[reviewed by [@B7], [@B32], and [@B37]\]. Despite similar physiological changes in LTF and VAH, several lines of evidence have been used to argue that the signaling mechanisms for LTF do not explain VAH. For example, LTF is well-known to require activation of serotonin receptors ([@B3]; [@B5]) but serotonin receptor blockade does not reverse VAH after 4 h of hypoxia in goats ([@B15]), and whole-body serotonin depletion in rats does not block VAH after 1 day of sustained hypoxia ([@B28]). Also, exposure to sustained hypoxia for 25 min (i.e., a continuous exposure equal to the total duration of hypoxia in an intermittent hypoxia protocol that causes LTF) does not cause LTF ([@B8]). Effects of longer exposure to hypoxia, such as 7 days used to show plasticity in CNS respiratory centers ([@B32]), have not been studied though.

More recently, a second mechanism for LTF that depends on adenosine receptors and more severe levels of intermittent hypoxia has been described ([@B26]; reviewed in [@B31]). Exposure to moderate levels of intermittent hypoxia (arterial P~O2~ = 45--55 mm Hg) induces LTF by a serotonin-dependent pathway but exposure to more severe intermittent hypoxia (arterial P~O2~ = 25--35 mm Hg) also activated an adenosine-dependent pathway to induce LTF ([@B26]). Increased phrenic nerve activity does not strictly depend on intermittent hypoxia *per se* and can be induced by direct pharmacological activation of serotonin 5-HT~2~ receptors ([@B22]) or adenosine A~2A~ receptors ([@B13]). Both of these pathways depend on G-protein coupled receptor (GPCR) signaling but they involve different GPCR pathways. The serotonergic or "Q pathway" depends on activation of G~Q~ protein, increased levels of BDNF and phosphorylation of ERK protein to induce phrenic LTF ([@B36]). The adenosine or "S pathway" depends on activation of G~S~ protein, PKA and phosphorylation of AKT ([@B8]). Since the blocking of one these pathways can increase LTF, G~S~ and G~Q~ signaling interact via cross-talk inhibition ([@B7]; [@B8]; [@B25]).

The role of adenosine-dependent G~S~ mechanisms in VAH, and the contribution serotonin-dependent G~Q~ mechanisms to exposures to sustained hypoxia longer than 1 day have not been studied. We hypothesized that longer exposure to moderate hypoxia could activate the adenosine-G~S~ pathway described for LTF in severe intermittent hypoxia and contribute to VAH. To test this, we measured the hypoxic and hypercapnic ventilatory response in rats exposed to 7 days of CH with chronic blockade of adenosine A~2A~ receptors during CH. We also tested the effects of chronic serotonin 5-HT~2~ receptor blockade during 7 days of CH, and the effects of acute A~2A~ and 5-HT~2~ receptor blockade after VAH was established, to compare signaling mechanisms during VAH and LTF.

Materials and Methods {#s1}
=====================

Animals
-------

Experiments were performed in male Sprague-Dawley rats (Harlan) weighing 250--300 g housed in 12:12 h light dark cycle and fed with standard diet *at libitum* except during measurements in the plethysmograph. All the experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.

Chronic Hypoxia
---------------

The rats were exposed to CH in a hypobaric chamber for 7 days (barometric pressure = 380 Torr, P~IO2~ = 70 Torr, temperature 21°C and 40% humidity), and normoxic control rats were housed in the same conditions in the room outside the chamber. The chamber was opened every other day for cage cleaning, and replacement of food and water.

Plethysmography
---------------

Ventilatory responses to hypoxia and hypercapnia were measured in unrestrained rats using a whole body barometric plethysmograph (7 L) modified for continuous flow ([@B35]; [@B29]). Briefly, flow was maintained constant through the chamber while a pressure transducer (mMP45 with 2 cmH2O diaphragm, Validyne) recorded the changes attributable to warming and expansion of inhaled gasses. On the experimental day, the rats were weighed and sealed into the plethysmograph chamber along with a temperature and humidity probe (Thermalert TH5, Physitemp). A constant gas flow (3 l/min) was delivered with a mass flow controller and gas mixer (MFC-4 Sable Systems) upstream of the chamber. Gasses exited the chamber through a valve and into a vacuum pump (Model 25, Precision Scientific) to isolate pressure changes from breathing in the chamber during constant flow with high input and output impedances. This also allowed us to maintain chamber pressure near-atmospheric pressure and reference pressure measurements in the chamber to atmosphere. Inspired and expired carbon dioxide fractions were measured with an O2/CO2 analyzer (FOXBOX Field Analysis system, Sable Systems) sampling from the chamber.

Ventilatory Response Measurements
---------------------------------

We measured the HVR and the hypercapnic ventilatory response (HCVR) with the following protocols. For normoxic control animals, we put rats in the plethysmograph for 45 min of acclimation to 21% O~2~, followed by 5 min of exposure to 10% O~2~ to further acclimate rats to the experimental conditions, i.e., changes in inspired gasses. Then we returned rats to 21% O~2~ for 15 min for the first measure of ventilation in baseline conditions (normoxia in this case). Rats were exposed to 10% O~2~ for 15 min~,~ returned to baseline conditions for 15 min, exposed to 7%CO~2~/21%O~2~ for 15 min, and finally returned to baseline conditions for 15 min. The protocol was similar but opposite for CH rats. In this case, the baseline condition was 10% O~2~ and they were acclimated to changes in inspired gas by exposure to 21% O~2~ for 5 min. The HVR in CH rats was measured by exposing them to 21% O~2~ for 15 min after a baseline breathing 10% O~2~.

All ventilatory parameters were recorded on an analog-digital acquisition system (PowerLab 8SP, AD Instruments) and analyzed with the LabChart 8-Pro Software, sampling at a rate of 1 kHz. We analyzed a minimum of 30 s between 10 and 15 min after changing gas concentrations for respiratory frequency (f~R~), tidal volume (V~T~) and their product, inspired ventilation (![](fphys-09-00860-i001.jpg)[I]{.smallcaps}), which was normalized to body mass \[ml/(min⋅kg)\] using 0.2-ml calibration pulses ([@B10]; [@B17]).

Serotonin and Adenosine Receptor Antagonist Administration
----------------------------------------------------------

We designed two studies to determine the effects of serotonin and adenosine on VAH using ketanserin (an antagonist of serotonin 5HT~2~ receptors) and MSX-3 (an antagonist adenosine A~2A~ receptors). Firstly, to test the role of 5HT~2~ and A~2A~ receptors on VAH during CH exposure, we administered ketanserin tartrate (Tocris, Minneapolis, MN, United States) or MSX-3 hydrate (Sigma--Aldrich, St. Louis, MO, United States) continuously using osmotic pumps (1 mg/Kg/day for both). Rats were initially anesthetized with isofluorane (initially 5% and maintained with 1--2% in 100% O~2~) and we implanted mini osmotic pumps (Model 2002, Alzet Osmotic Pumps, Cupertino, CA, United States) filled with ketanserin or MSX-3 dissolved in 40% DMSO/Saline subcutaneously 1 day before start the CH exposure. Vehicle control rats were implanted with osmotic pumps filled with 40% DMSO/Saline (Vehicle). After surgery, rats were administrated with bupenophirine (0.03 mg/Kg, i.p.) and enrofloxacin (4 mg/Kg, i.p.).

Secondly, to assess the effect of 5HT~2~ (Ketanserin) or A~2A~ (MSX-3) antagonists on VAH after it was established by CH, we studied a different group of rats and measured ventilatory responses in the same individuals before and after exposure to CH (7 days). Then we injected Ketanserin or MSX-3 (1 mg/Kg i.p.) and returned the rats to hypobaric CH for an additional day. The next day, we injected the rats with antagonists again and repeated the ventilatory measurements.

Statistics
----------

Data was expressed as mean ± SEM. Statistical analysis was performed using two-way ANOVA between drug and CH effect or repeated measurement ANOVA test followed by Bonferroni *post hoc* analysis (GraphPad Prism, 5.0, United States). *p* \< 0.05 was set as the level of statistical significance.

Results
=======

Chronic Serotonin 5HT~2~ Receptor Blockade During CH Decreased Ventilatory Acclimatization to Hypoxia
-----------------------------------------------------------------------------------------------------

To determine the contribution of serotonin receptors on VAH we studied the effect of the 5HT~2~ receptor antagonist ketanserin administrated continuously in rats during exposure to CH. ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} increased with acute hypoxia (10% O~2~) and CH as expected for a normal HVR and VAH (**Figure [1](#F1){ref-type="fig"}**). In rats breathing 21% O~2~, there was a significant interaction for ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} between chronic O~2~ level and ketanserin (*p* = 0.0001). *Post hoc* analysis showed ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} was significantly decreased by ketanserin after CH (**Figure [1B](#F1){ref-type="fig"}**) but not in normoxic control conditions (**Figure [1A](#F1){ref-type="fig"}**). In rats breathing 21% O~2~, the decrease in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} was explained by a significant decrease in V[T]{.smallcaps}, which showed a significant interaction between chronic O~2~ and drug (*p* = 0.01) (**Figures [1E,F](#F1){ref-type="fig"}**) while f[R]{.smallcaps} no longer showed a significant increase with drug after CH, which had been observed in normoxic controls (**Figures [1C,D](#F1){ref-type="fig"}**); the interaction of chronic O~2~ level and ketanserin on f[R]{.smallcaps} was significant (*p* = 0.0292).

![Effect of 5HT~2~ antagonist on ventilation in control (Normoxic) rats and rats acclimatized to chronic hypoxia (CH). **(A)** Blocking 5HT~2~ receptors with ketanserin in Normoxic rats increased ventilation (![](fphys-09-00860-i001.jpg)[I)]{.smallcaps} in acute hypoxia (10% O~2~) and had no significant effect during normoxia (21% O~2~). **(B)** CH significantly increased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} with vehicle; ketanserin significantly decreased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in CH rats during acute hypoxia and normoxia, in contrast to normoxic controls. **(C--F)** ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} increased with ketanserin in Normoxic rats because of frequency (f[R]{.smallcaps}) but it decreased with ketanserin in CH rats because of tidal volume (V[T]{.smallcaps}). ^∗^*p* \< 0.05, Bonferroni after two-way ANOVA, *n* = 6 rats per group.](fphys-09-00860-g001){#F1}

The effects of ketanserin in rats breathing 10% O~2~ were similar to those observed when breathing 21% O~2~ (**Figure [1](#F1){ref-type="fig"}**). ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} showed a significant interaction between chronic O~2~ level and ketanserin (*p* \< 0.0001) with ketanserin significantly decreasing ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in 10% O~2~ after CH, in contrast to significantly increasing it in normoxic control rats (**Figures [1A,B](#F1){ref-type="fig"}**). Ketanserin significantly increased f[R]{.smallcaps} in normoxic control rats during acute hypoxia while changes in f[R]{.smallcaps} with ketanserin were not significant in acute hypoxia after CH (**Figures [1C,D](#F1){ref-type="fig"}**). The interaction for chronic O~2~ level and ketanserin were not significant for V[T]{.smallcaps} breathing 10% O~2~ although it tended to decrease with ketanserin after CH (**Figures [1E,F](#F1){ref-type="fig"}**).

**Table [1](#T1){ref-type="table"}** shows no significant effect of ketanserin on ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in rats breathing 7% CO~2~ before or after CH. ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} increased during hypercapnia after CH in all cases, as expected for acclimatization. Hence, differences observed in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} and the HVR with ketanserin after CH are not explained by hypercapnic responses or general changes in ventilatory drive. **Table [2](#T2){ref-type="table"}** shows metabolic rates (CO~2~ production, ![](fphys-09-00860-i001.jpg)[~CO2~]{.smallcaps}) were not significantly different between normoxic control and CH rats \[23.2 ± 0.6 and 26.2 ± 2.0 (ml/(kg min))\], with vehicle or ketanserin breathing 21 or 10% O~2~. Hence, the differences in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} found between conditions are not explained by differences in the effects of metabolism on ventilatory drive.

###### 

Responses to hypercapnia in rats treated with 5HT~2~ and A~2A~ receptor antagonists during CH exposure.

  ![](fphys-09-00860-i001.jpg)[~I~]{.smallcaps} (mL/min^∗^Kg)   Normoxia     CH                        
  ------------------------------------------------------------- ------------ ------------ ------------ ---------------
  Vehicle                                                       1560 ± 68    4008 ± 364   3764 ± 87    7958 ± 859 \*
  Ketanserin                                                    1983 ± 219   4594 ± 429   3097 ± 157   8150 ± 627 \*
  MSX-3                                                         1983 ± 151   4962 ± 425   2961 ± 157   7647 ± 871 \*
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###### 

Metabolic rates in rats treated with 5HT~2~ and A~2A~ receptor antagonists during CH exposure.

  Group              O~2~ (%)   ![](fphys-09-00860-i001.jpg)[~CO2~]{.smallcaps} \[mL/(in^∗^Kg)\]   
  ------------------ ---------- ------------------------------------------------------------------ ------------
  Normoxia vehicle   21         23.2 ± 0.6                                                         23.2 ± 0.6
  Normoxia drug                 21.2 ± 0.8                                                         25.8 ± 1.5
  CH vehicle                    26.2 ± 2.0                                                         26.4 ± 2.3
  CH drug                       20.9 ± 0.5                                                         25.3 ± 2.3
  Normoxia vehicle   10         21.8 ± 0.6                                                         21.8 ± 0.6
  Normoxia drug                 21.3 ± 0.4                                                         23.8 ± 0.9
  CH vehicle                    22.6 ± 1.8                                                         22.4 ± 1.5
  CH drug                       22.4 ± 1.3                                                         22.5 ± 1.5
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) of rats treated with ketanserin and MSX-3 or vehicle during normoxic or chronic hypoxia (CH). No significant differences between conditions. Bonferroni's test after two-way ANOVA,

n

= 5--6.

Summarizing, 5HT~2~ receptor blockade during CH blunted the increase in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in 10% O~2~ that normally occurs with VAH and decreased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in 21% O~2~ by a similar amount, i.e., there was a parallel downward shift of the HVR curve (![](fphys-09-00860-i001.jpg)[I]{.smallcaps} versus inspired O~2~). This was mainly due to an effect of ketanserin on V[T.]{.smallcaps} Ketanserin increased f[R]{.smallcaps} in 21% and 10% O~2~ in normoxic control but not CH rats, which had a higher f[R]{.smallcaps} that was similar to the elevated level caused by ketanserin in the normoxic controls.

Chronic Adenosine A~2A~ Receptor Blockade During CH Exposure Decreased Ventilatory Acclimatization to Hypoxia
-------------------------------------------------------------------------------------------------------------

**Figure [2](#F2){ref-type="fig"}** shows that the general pattern of changes in ventilation after CH with the A~2A~ antagonist MSX-3 were similar to those described above for effects of 5HT~2~ receptor blockade. ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} increases with acute hypoxia and CH as expected for a normal HVR and VAH (**Figures [2A,B](#F2){ref-type="fig"}**). ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} breathing 21% O~2~ showed a significant interaction between chronic O~2~ level and MSX-3 (*p* = 0.0005) as MSX-3 tended to increase ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in normoxic control rats (**Figure [2A](#F2){ref-type="fig"}**) and significantly decreased it in CH rats (**Figure [2B](#F2){ref-type="fig"}**). We observed similar patterns of change in f[R]{.smallcaps} and [VT]{.smallcaps} with a significant interaction between chronic O~2~ level and MSX-3 for V[T]{.smallcaps} (*p* = 0.0002) and f[R]{.smallcaps} (*p* \< 0.0001) (**Figures [2C](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}**). The effects of MSX-3 during 10% O~2~ breathing was similar; there was a significant interaction between chronic O~2~ level and MSX-3 for ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} (*p* \< 0.0011) so ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} was significantly decreased by MSX-3 after CH (*p* \< 0.05) in contrast to a significant increase (*p* \< 0.05) in the normoxic control rats.

![Effect of A~2A~ antagonist on ventilation in control (Normoxic) rats and rats acclimatized to chronic hypoxia (CH). **(A)** Blocking A~2A~ receptors with MSX-3 in Normoxic rats increased ventilation (![](fphys-09-00860-i001.jpg)[I)]{.smallcaps} in acute hypoxia (10% O~2~) and had no significant effect during normoxia (21% O~2~). **(B)** CH significantly increased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} with vehicle but MSX-3 significantly decreased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in CH rats during acute hypoxia and normoxia, in contrast to normoxic controls. **(C--F)** There were no significant effects of MSX-3 on respiratory frequency (f~R~) or tidal volume (V~T~). ^∗^*p* \< 0.05, Bonferroni after two-way ANOVA, *n* = 6 rats per group.](fphys-09-00860-g002){#F2}

**Table [1](#T1){ref-type="table"}** shows that these changes in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} with MSX-3 treatment were not due to changes in the ventilatory response to CO~2,~ which was not significantly different between vehicle and drug. ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} increased during hypercapnia after CH in all cases, as expected for acclimatization. Also, ![](fphys-09-00860-i001.jpg)[~CO2~]{.smallcaps} was not significantly different between normoxic control and CH rats with vehicle or MSX-3 breathing 21 or 10% (**Table [2](#T2){ref-type="table"}**). Hence, the differences in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} found between conditions are not explained by differences in the effects of metabolism on ventilatory drive.

Summarizing, A~2A~ receptor blockade during CH blunted the increase in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in 10 and 21% O~2~ that normally occur with VAH by a similar amount so there was a parallel downward shift of the HVR curve (![](fphys-09-00860-i001.jpg)[I]{.smallcaps} comparing acute O~2~ level, 21 versus 10% O~2~). This was due effects of MSX-3 on both f[R]{.smallcaps} and V[T.]{.smallcaps}

Acute Administration of Ketanserin After CH Did Not Reverse VAH
---------------------------------------------------------------

To test if 5HT~2~ receptor blockade affects ventilatory responses after VAH is already established, we measured the ventilation in the same rats (1) before and (2) after 7 days of CH, and (3) after 2 more days of CH with two acute doses of ketanserin (1 mg i.p./kg daily). CH caused a significant increase of ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} during 21 or 10% O~2~ breathing (**Figure [3A](#F3){ref-type="fig"}**). Ketanserin administered for 2 days more of CH did not cause any significant difference in the HVR versus CH alone (**Figure [3A](#F3){ref-type="fig"}**). However, ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in 21% O~2~ breathing after CH + ketanserin resulted from a significantly decreased f[R]{.smallcaps} and increased V[T]{.smallcaps} (**Figures [3B,C](#F3){ref-type="fig"}**). Ketanserin did not affect neither ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in 7% CO~2~ (**Table [3](#T3){ref-type="table"}**) nor metabolic rates (**Table [4](#T4){ref-type="table"}**) after VAH was established.

![Repeated measurements blocking 5HT~2~ receptors after VAH was established. Blocking 5HT~2~ receptors with ketanserin after chronic sustained hypoxia (CH) has no effect on ventilation (![](fphys-09-00860-i001.jpg)[I,]{.smallcaps} **A**), respiratory frequency (f~R~, **B**) or tidal volume (V~T~, **C**) during normoxia (21% O~2~) or acute hypoxia (10% O~2~). ^∗^*p* \< 0.05, Bonferroni after repeated measurements two-way ANOVA, *n* = 10 rats.](fphys-09-00860-g003){#F3}

###### 

Responses to hypercapnia in rats treated with 5HT~2~ and A~2A~ receptor antagonists after CH exposure.

  Drug                  Group       ![](fphys-09-00860-i001.jpg)~I~ (mL/min^∗^Kg)   
  --------------------- ----------- ----------------------------------------------- ----------------
  Ketanserin (η = 10)   Control     1013 ± 47                                       4195 ± 573
                        CH          1959 ± 128                                      7683 ± 1186^∗^
                        CH + Drug   1871 ± 107                                      6824 ± 1010^∗^
  MSX-3 (η = 9)         Control     1163 ± 79                                       4791 ± 654
                        CH          1777 ± 118                                      6624 ± 778^∗^
                        CH + Drug   2396 ± 90                                       7340 ± 969^∗^
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###### 

Metabolic rates in rats treated with 5HT~2~ and A~2A~ receptor antagonists after CH exposure.

  Drug                  Group       ![](fphys-09-00860-i001.jpg)[~CO2~]{.smallcaps} \[mL/(min^∗^Kg)\]   
  --------------------- ----------- ------------------------------------------------------------------- ------------
  Ketanserin (η = 10)   Control     8.6 ± 1.0                                                           11.4 ± 0.9
                        CH          12.8 ± 1.5                                                          13.2 ± 1.0
                        CH + Drug   15.7 ± 1.5                                                          15.7 ± 1.5
  MSX-3 (η = 9)         Control     11.2 ± 0.5                                                          12.6 ± 0.5
                        CH          13.4 ± 1.3                                                          13.9 ± 1.4
                        CH + Drug   14.4 ± 1.2                                                          15.0 ± 0.9
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Acute Administration of MSX-3 After CH Increased Ventilation
------------------------------------------------------------

To test if the A~2A~ receptor blockade had an effect after VAH was established, we measured ventilatory responses using repeated measurements in rats during (1) normoxic control conditions, (2) after 7 days of CH, and (3) after 2 additional days of CH with acute injections of MSX-3 (1 mg/kg i.p. daily). Exposure to CH produced a significant increase of ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in rats breathing 21 or 10% O~2~ (**Figure [4A](#F4){ref-type="fig"}**). MSX-3 produced additional increases of ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in both, 21 and 10% O~2~ breathing (**Figure [4A](#F4){ref-type="fig"}**). This was due to significant effects of MSX-3 on f[R]{.smallcaps} and V[T]{.smallcaps} during 21% O~2~ breathing and on non-significant increases of f[R]{.smallcaps} and V[T]{.smallcaps} during 10% O~2~ breathing (**Figures [4B,C](#F4){ref-type="fig"}**). MSX-3 administration after VAH was established by CH did not have significant effects on CH-induced increases in ventilation during 7% CO~2~ breathing (**Table [3](#T3){ref-type="table"}**) nor produce changes in metabolic rate (**Table [4](#T4){ref-type="table"}**).

![Repeated measurements blocking A~2A~ receptors after VAH was established. Blocking A~2A~ receptors with MSX-3 after CH increased ventilation (![](fphys-09-00860-i001.jpg)[I, **A**]{.smallcaps}), more than CH alone in acute hypoxia or normoxia. This was caused by significant increases in respiratory frequency (f~R~, **B**) and tidal volume (V~T~, **C**) in normoxia (21% O~2~) that were not observed in acute hypoxia (10% O~2~). ^∗^*p* \< 0.05, Bonferroni after repeated measurement two-way ANOVA, *n* = 9 rats.](fphys-09-00860-g004){#F4}

Discussion
==========

We found that chronic inhibition of either serotonin 5HT~2~ or adenosine A~2A~ receptors *during* chronic hypoxia decreased VAH: ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} breathing normoxic or hypoxic gas increased with CH plus drug significantly less than with CH plus vehicle. In contrast, acute blockade of 5HT~2~ receptors *after* VAH had been established by CH had no effect on ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} and acute blockade of adenosine A~2A~ receptors after VAH had been established actually increased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} breathing normoxic or hypoxic gas (relative to CH without drug). We found no changes in metabolic rates between conditions that could cause other changes in ventilatory drive. Also we found no differences in ventilatory responses to CO~2~ with drug treatments indicating that the effects of drugs were specific to hypoxic responses and any increases or decreases in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} observed with drugs were not generalized increases in ventilatory drive or ventilatory limitations, respectively. Hence our results support a role for G~Q~ and G~S~ signaling in establishing ventilatory acclimatization to sustained hypoxia for 7 days. Furthermore, the different effects of GPCR antagonists during versus after CH might be explained by changes in cross-talk inhibition between G~Q~ and G~S~ pathways, activated by 5HT~2~ and A~2A~ receptors respectively. Both of these mechanisms have been shown to be important for chemoreflex plasticity with intermittent hypoxia in LTF but this is the first evidence for them with VAH from CH. However, it is important to note that we have not identified the site of action for these drug effects and we have not actually tested elements of the specific signaling pathways being activated by these receptors.

G~Q~ Signaling During Chronic Hypoxia and Ventilatory Acclimatization
---------------------------------------------------------------------

In normoxic control rats, we found no effect of chronic 5HT~2~ receptor blockade with ketanserin on ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} during normoxia. In normoxic control rats breathing 10% O~2~ or 21% O~2~ f[R]{.smallcaps} and ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} significantly increased (**Figure [1](#F1){ref-type="fig"}**). Similar increases in phrenic nerve responses to acute hypoxia following acute administration of ketanserin to anesthetized normoxic control rats have been reported, although f[R]{.smallcaps} increased more than V[T]{.smallcaps} in those experiments ([@B19]).

As expected, CH increased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps}, in rats breathing 21 or 10% O~2~ but chronic ketanserin during CH significantly decreased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} at both levels of inspired O~2~, mainly by effects of V[T]{.smallcaps} (**Figure [1](#F1){ref-type="fig"}**). These effects of blocking serotonin receptors and presumably G~Q~ signaling on ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in CH rats breathing normoxic gas are similar to those found for ventilatory and phrenic long term facilitation (vLTF and pLTF, respectively). Methysergide (a general 5HT receptor antagonist) administered before moderate acute intermittent hypoxia (IH), prevents phrenic LTF and specifically increased amplitude in integrated phrenic activity for 30--90 min after intermittent hypoxia ([@B3]). Also, administering ketanserin 20 min before moderate IH prevents the development of phrenic LTF ([@B19]; [@B12]) and ketanserin 1 day before additional to immediately before moderate IH blocks ventilatory LTF ([@B23]).

The effects of blocking 5HT~2~ receptors and presumably G~Q~ signaling on ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in rats breathing hypoxic gas appears to be different after IH versus CH. However, we found chronic ketanserin decreased the normal increase in ![](fphys-09-00860-i001.jpg)[I,]{.smallcaps} during 10% O~2~ breathing with CH, thereby blunting the increase in acute HVR that occurs with VAH. This can be compared to the effects of ketanserin on progressive augmentation (PA), which is observed in studies of LTF with IH protocols as increases in ventilation or phrenic activity during successive bouts of hypoxia ([@B32]). The effects of IH on ventilatory drive during normoxia and hypoxia have been distinguished as LTF and PA, respectively, in part because LTF and PA seem to involve different mechanisms; PA is not sensitive to serotonin receptor antagonists in contrast to LTF \[reviewed by [@B32]\]. Hence the effects of G~Q~ signaling on ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in hypoxia appear to differ following CH versus IH. The duration of hypoxic exposure, duration of 5HT~2~ receptor blockade, and/or effects of blocking 5HT~2~ receptors outside the spinal cord may explain differences in the effects of ketanserin between studies.

G~S~ Signaling During Chronic Hypoxia and Ventilatory Acclimatization
---------------------------------------------------------------------

The second mechanism for LTF operative during severe intermittent hypoxia was first described in a pharmacological study designed to test the hypothesis that phrenic motor facilitation (pMF) could be elicited by direct stimulation of a signaling pathways involving A~2A~ receptors, mimicking brain derived neurotrophic factor (BDNF), which was known to be necessary and sufficient for LTF with moderate IH ([@B13]). The study found activating spinal adenosine A~2A~ receptors produced pMF in anesthetized rats and increased normoxic ventilatory drive in conscious rats. Subsequently, this adenosine mechanism has been shown to work by G~S~ signaling and contributes to LTF with severe IH as demonstrated by decreased LTF following spinal (intrathecal) administration of MSX-3 ([@B26]). We hypothesized that longer exposure to moderate hypoxia may result in a comparable "dose" of hypoxia and evoke this mechanism to contribute to VAH with days of CH.

In normoxic control rats, chronic systemic blockade of A~2A~ receptors and presumably G~S~ signaling with MSX-3 did not affect ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} breathing 21% O~2~ but it did increase ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} breathing 10% O~2~ (**Figure [2A](#F2){ref-type="fig"}**). Spinal MSX-3 has no effect on phrenic nerve activity during normoxia in anesthetized rats using severe IH for LTF studies ([@B26]), which agrees with our results in normoxic controls breathing 21% O~2~. However, MSX-3 did not affect PA in the LTF study ([@B26]), in contrast to the increase we would predict from effects we observed in acute hypoxia (**Figure [2A](#F2){ref-type="fig"}**). The duration of hypoxic exposure, duration of A~2A~ receptor blockade, effects of A~2A~ receptor blockade in other parts of the reflex pathway outside the spinal cord, and/or wakefulness may explain differences in the effects of MSX-between studies.

Effects of Blocking G~S~ and G~Q~ Signaling After Ventilatory Acclimatization Is Established
--------------------------------------------------------------------------------------------

Acute administration of ketanserin after VAH was established by CH did not change ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in rats breathing 21 or 10% O~2~ (**Figure [3](#F3){ref-type="fig"}**). These results agree with experiments done in goats were administration of ketanserin did not produce significant changes after sustained hypoxia ([@B14]). In contrast, acute administration of MSX-3 after VAH was established by CH increased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} in rats breathing 21 or 10% O~2~ (**Figure [4](#F4){ref-type="fig"}**). Note that this is opposite the effect of MSX-3 to decrease ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} when administered during CH (compare **Figures [2](#F2){ref-type="fig"}**, **[4](#F4){ref-type="fig"}**). This might be explained by cross-talk inhibition between G~S~ and G~Q~ signaling that has been demonstrated recently for pMF ([@B16]; [@B8]). In a model proposed for such crosstalk (see Figure 6, [@B9]), G~S~ and G~Q~ signals following moderate acute sustained hypoxia (ASH) cancel each other so pMF is not observed. However, blocking adenosine A~2A~ receptors with MSX-3 disinhibits a 5-HT~2~ receptor-dependent mechanism in moderate ASH and reveals pMF (i.e., increases phrenic activity in normoxia after moderate ASH). In contrast, blocking 5-HT~2~ receptors in moderate ASH does not increase phrenic activity; the A~2A~ adenosine pathway is disinhibited but it is not sufficiently activated by moderate ASH to cause pMF. *Severe* ASH does activate the A~2A~ adenosine mechanism, however, and 5HT~2~ antagonists do increase pMF following severe ASH.

Hence, our results showing increased ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} with MSX-3 after CH agree better with plasticity induced in phrenic nerve activity by moderate versus severe ASH. We observed increases in ![](fphys-09-00860-i001.jpg)[I]{.smallcaps} after MSX-3 but not ketanserin administered after VAH was established. Also, the increases with MSX-3 after CH were greater in 21 than 10% O~2~ breathing (**Figure [4](#F4){ref-type="fig"}**), similar to the significant effect of MSX-3 after moderate ASH on phrenic activity in normoxia (i.e., pMF) but not on the phrenic response to hypoxia (see Figure 2, [@B9]). Together, the data do not support our hypothesis that longer durations of moderate sustained hypoxia act more like shorter exposures to severe hypoxia. However, the level of hypoxia in our awake preparations was intermediate to moderate and severe hypoxia in these other studies (e.g., [@B9]) with arterial P~O2~ being measured as 37--42 Torr in other studies of rats breathing 10% O~2~ before or after acclimatization ([@B1]; [@B34]). A meta-analysis of the effects of different patterns of IH on LTF shows that the physiological consequences (e.g., hypertension versus motor nerve facilitation) depend on both the level of hypoxia and the duration of hypoxia (i.e., total number of IH bouts) ([@B25]). Further study is needed to draw any firm conclusions about the level of P~O2~ necessary to evoke specific mechanisms of plasticity with short versus long-term hypoxia.

Limitations
-----------

Our results support both similarities and differences in G~Q~ and G~S~ signaling for plasticity in ventilatory control with CH and intermittent hypoxia. However, as noted above, we did not actually study specific signaling mechanisms but the effects of blocking GPCR that initiate these signaling pathways. Also, it is important that the site of action of drug effects in our experiments cannot be localized because drugs were administered systemically. Specifically, we have not studied the effects of receptor or signaling blockade in phrenic or hypoglossal motor neurons, which are primary sites of plasticity for LTF ([@B3]; [@B12]; [@B5]). The drug effects we studied could be occurring at phrenic motor neurons but also at the at the carotid bodies, which increase O~2~-sensitivity with CH ([@B21]), and/or the nucleus tractus solitarii, which exhibits plasticity contributing to VAH and is the site of the primary synapse from carotid body chemoreceptors is in the CNS ([@B32]). While this limits our ability to localize and test precise mechanisms, it also described the physiological consequences of systemic therapeutics acting on these mechanisms as they would occur in a clinical situation without targeted application.

The effects we observed could certainly involve phrenic motor neurons, where G~Q~ and G~S~ signaling have been described for LTF (see above). However, the changes in ventilation that we observed with ketanserin could be explained also by serotonin effects at 5-HT~2~ receptors in the carotid body, which contribute to increased O~2~-sensitivity with chronic intermittent hypoxia \[i.e., "sensory LTF," reviewed by [@B33] and [@B21]\] and produced a prolonged chemosensory response to hypoxia ([@B18]). Similarly, MSX-3 administration could involve effects on the peripheral chemoreceptors, since adenosine is modulating the activity of the carotid bodies acting through A~2A~ receptors ([@B27]; [@B6]). [@B20] proposed that adenosine inhibits voltage-dependent Ca^2+^ currents in the glomus cells, suggesting that activation of A~2A~ receptors have a inhibitory effect on the carotid body activity. On the other hand, a recent publication from [@B38] demonstrated that adenosine A~2A~ receptors have a pre and postsynaptic effects in glomus cell and petrosal ganglion neuron co-cultures, which is consistent with the excitatory effects of adenosine in the carotid bodies observed by other authors ([@B11]; [@B27]; [@B6]).

We have been especially interested in plasticity in the NTS, which is important for VAH as discussed above. Serotonin 5-HT~2A~ receptors have been reported in the NTS and to explain in excitatory postsynaptic currents ([@B2]). Adenosine A~2A~ receptors in the NTS are reported to attenuate sympathetic reflexes ([@B24]) but their role in the ventilatory control has not been determined. Further investigation into possible roles for serotonin 5-HT~2A~ and adenosine A~2A~ receptors in the NTS on ventilatory chemoreflexes and testing their potential contribution to plasticity demonstrated for glutamatergic neurotransmission in the NTS with VAH ([@B29],[@B30]), still need to be investigated. Serotonin acting at central as well as peripheral sites in high altitude adapted pikas modulates the HVR ([@B4]), so there is a precedent for serotonergic effects in the CNS as well as at the carotid bodies.

Conclusion
==========

The effect of manipulating G~Q~ and G~S~ signaling by blocking 5HT2 and A2a receptors, respectively, appear more similar for VAH and LTF in rats breathing normoxic versus hypoxic gas, and these effects are different before and after VAH is established. We also found some evidence for cross-talk between G~Q~ and G~S~ signaling in VAH but it was not reciprocal as demonstrated for LTF. However, all of these ideas need further research. Most LTF studies do not focus on changes in the hypoxic response like VAH studies do, but rather the long-term changes in normoxic ventilatory drive. Most importantly, we need to determine the neuroanatomical substrate for these effects in VAH and the role of these signaling pathways in chemoreceptors, CNS integrative centers and motor neurons.
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